Is this a side effect of therapy or is independent from neurologic disease? We have 28 patients treated with Duodopa since January2012;an important percent of them developed polyneuropathy after initiating this therapy. Objective: To determine the etiologic factors and the correct management in order to prevent this affection. Material and methods: We studied 28 patients with advanced PD in treatment with LCIG;They were examined by EMG(Electromyography) serum level of B12 before treatment and 6 and 12 months after Duodopa treatment. The objectives of this study were to evaluate the risk of neuropathy in patients with Parkinson's disease and to evaluate the role of levodopa exposure as a potential risk factor. Results: We found some cases of severe sensorimotor polyneuropathy with both subacute and chronic onsets, rarely associated with vitamin B12 imbalance. We did not observed severe changes in vitamin B12 level. This may reflect a rare complication or a severe side effect. Conclusion: We describe 28 PD patientswho developed axonal polyneuropathy and vitamin B(12) deficiency. Wereview the potential etiologic factors, and discuss about the algorithm for themanagement and prevention of this simptomatology. Our research suggest a relationshipbetween levodopa/carbidopa intestinal gel and PN.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.